Superstring Capital Management
Latest statistics and disclosures from Superstring Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CYTK, NKTX, ETNB, BBIO, SVRA, and represent 42.70% of Superstring Capital Management's stock portfolio.
- Added to shares of these 10 stocks: NKTX (+$9.1M), CYTK (+$7.1M), SVRA (+$6.2M), CABA, BBIO, AVTE, APGE, DYN, PRAX, VRNA.
- Started 17 new stock positions in TRML, LYRA, AUPH, Alpine Immune Sciences, PRAX, ANNX, KALV, PEPG, RNA, ASND. CABA, DYN, ALLK, CTMX, AVTE, PYXS, APGE.
- Reduced shares in these 10 stocks: , PTGX (-$8.7M), IMVT (-$8.6M), , LNTH, IONS, KROS, SLRN, KRYS, QTRX.
- Sold out of its positions in SLRN, Fusion Pharmaceuticals, ImmunoGen, IMVT, KRYS, LNTH, NBIX, PTGX, QTRX, IMTX.
- Superstring Capital Management was a net buyer of stock by $8.0M.
- Superstring Capital Management has $151M in assets under management (AUM), dropping by 7.95%.
- Central Index Key (CIK): 0001931118
Tip: Access up to 7 years of quarterly data
Positions held by Superstring Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv![Download consolidated filings csv](/static/img/csv.png)
![Download consolidated filings xlsx](/static/img/microsoft-excel.png)
Portfolio Holdings for Superstring Capital Management
Superstring Capital Management holds 37 positions in its portfolio as reported in the March 2024 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Cytokinetics Com New (CYTK) | 12.9 | $20M | +57% | 279k | 70.11 |
|
Nkarta (NKTX) | 8.5 | $13M | +242% | 1.2M | 10.81 |
|
89bio (ETNB) | 7.2 | $11M | -7% | 941k | 11.64 |
|
Bridgebio Pharma (BBIO) | 7.2 | $11M | +71% | 354k | 30.92 |
|
Savara (SVRA) | 6.8 | $10M | +153% | 2.1M | 4.98 |
|
Ideaya Biosciences (IDYA) | 6.3 | $9.5M | -13% | 217k | 43.88 |
|
Fate Therapeutics (FATE) | 4.5 | $6.8M | +8% | 921k | 7.34 |
|
Day One Biopharmaceuticals I (DAWN) | 3.8 | $5.8M | -7% | 350k | 16.52 |
|
Roivant Sciences SHS (ROIV) | 3.7 | $5.6M | +62% | 531k | 10.54 |
|
Ionis Pharmaceuticals (IONS) | 3.5 | $5.2M | -36% | 121k | 43.35 |
|
Marinus Pharmaceuticals Com New (MRNS) | 3.4 | $5.1M | +22% | 566k | 9.04 |
|
Cabaletta Bio (CABA) | 3.3 | $5.0M | NEW | 291k | 17.06 |
|
Urogen Pharma (URGN) | 2.9 | $4.3M | +12% | 288k | 15.00 |
|
Verona Pharma Sponsored Ads (VRNA) | 2.8 | $4.2M | +109% | 259k | 16.09 |
|
Aerovate Therapeutics (AVTE) | 2.2 | $3.3M | NEW | 110k | 29.57 |
|
Apogee Therapeutics (APGE) | 2.0 | $3.0M | NEW | 45k | 66.45 |
|
Axsome Therapeutics (AXSM) | 1.9 | $2.9M | +126% | 37k | 79.80 |
|
Dyne Therapeutics (DYN) | 1.9 | $2.8M | NEW | 100k | 28.39 |
|
Praxis Precision Medicines I Com New (PRAX) | 1.6 | $2.4M | NEW | 40k | 61.02 |
|
Allogene Therapeutics (ALLO) | 1.5 | $2.3M | +134% | 521k | 4.47 |
|
Keros Therapeutics (KROS) | 1.5 | $2.2M | -54% | 34k | 66.20 |
|
Pyxis Oncology Common Stock (PYXS) | 1.4 | $2.1M | NEW | 494k | 4.26 |
|
Ascendis Pharma A/s Sponsored Adr (ASND) | 1.3 | $1.9M | NEW | 13k | 151.17 |
|
Pepgen (PEPG) | 1.1 | $1.7M | NEW | 114k | 14.70 |
|
Tourmaline Bio (TRML) | 1.1 | $1.6M | NEW | 70k | 22.90 |
|
Allakos (ALLK) | 1.0 | $1.6M | NEW | 1.2M | 1.26 |
|
Cytomx Therapeutics (CTMX) | 1.0 | $1.5M | NEW | 679k | 2.18 |
|
Annexon (ANNX) | 0.7 | $1.1M | NEW | 156k | 7.17 |
|
Avidity Biosciences Ord (RNA) | 0.6 | $945k | NEW | 37k | 25.52 |
|
Lyra Therapeutics (LYRA) | 0.6 | $904k | NEW | 145k | 6.22 |
|
Inozyme Pharma (INZY) | 0.6 | $864k | -9% | 113k | 7.66 |
|
Aurinia Pharmaceuticals (AUPH) | 0.3 | $494k | NEW | 99k | 5.01 |
|
Kalvista Pharmaceuticals (KALV) | 0.3 | $380k | NEW | 32k | 11.86 |
|
Alpine Immune Sciences | 0.2 | $358k | NEW | 9.0k | 39.64 |
|
Spruce Biosciences (SPRB) | 0.2 | $346k | +270% | 440k | 0.79 |
|
Ys Biopharma Ordinary Shares | 0.1 | $216k | 308k | 0.70 |
|
|
So Young International Sponsored Ads (SY) | 0.1 | $199k | -77% | 183k | 1.09 |
|
Past Filings by Superstring Capital Management
SEC 13F filings are viewable for Superstring Capital Management going back to 2023
- Superstring Capital Management 2024 Q1 filed May 15, 2024
- Superstring Capital Management 2023 Q4 filed Feb. 14, 2024